Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)

Phase 3Recruiting

0 views this week 0 watching⚡ Active🧠Featured in Neuroscience Pipeline Watch

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Secondary Progressive Multiple Sclerosis (SPMS)

Conditions

Secondary Progressive Multiple Sclerosis (SPMS)

Trial Timeline

Nov 11, 2025 → Jan 2, 2034

NCT ID

NCT07225504

About Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)

Remibrutinib (blinded) + Placebo + Remibrutinib (Open label) is a phase 3 stage product being developed by Novartis for Secondary Progressive Multiple Sclerosis (SPMS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07225504. Target conditions include Secondary Progressive Multiple Sclerosis (SPMS).

What happened to similar drugs?

13 of 20 similar drugs in Secondary Progressive Multiple Sclerosis (SPMS) were approved

Approved (13) Terminated (0) Active (7)

✅Cinacalcet HClKyowa KirinApproved

✅Paricalcitol + CalcifediolAbbVieApproved

✅Paricalcitol + Darbepoetin alfaAbbVieApproved

✅RanibizumabNovartisApproved

✅BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved

✅RanibizumabNovartisApproved

✅Sensipar® + Vitamin DAmgenApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07225504	Phase 3	Recruiting	Nov 11, 2025	Jan 2, 2034	Secondary Progressive Multiple Sclerosis (SPMS)

Competing Products

20 competing products in Secondary Progressive Multiple Sclerosis (SPMS)

See all competitors

Product	Company	Stage	Hype Score
ASP7991 + Cinacalcet + Placebo	Astellas Pharma	Phase 2	35
Fycompa	Eisai	Pre-clinical	26
Fycompa	Eisai	Pre-clinical	26
KHK7580 + KRN1493	Kyowa Kirin	Phase 2/3	38
KHK7580	Kyowa Kirin	Phase 1	29
KHK7580	Kyowa Kirin	Phase 3	40
KHK7580	Kyowa Kirin	Phase 3	40
Cinacalcet HCl	Kyowa Kirin	Approved	43
KHK7580 + Cinacalcet Hydrochloride	Kyowa Kirin	Phase 3	40
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493	Kyowa Kirin	Phase 2	35
dirucotide + Placebo	Eli Lilly	Phase 2/3	38
dirucotide	Eli Lilly	Phase 2/3	30
Paricalcitol + Calcitriol	AbbVie	Pre-clinical	18
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placebo	AbbVie	Phase 3	40
Paricalcitol + Calcifediol	AbbVie	Approved	43
Paricalcitol + Darbepoetin alfa	AbbVie	Approved	43
Birabresib Dose 20 mg	Merck	Phase 1	21
Ranibizumab	Novartis	Approved	43
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273	Novartis	Approved	43
Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT	Novartis	Phase 3	40